The global fetal bovine serum market revenue was US$ 840 million in 2021. The global fetal bovine serum market revenue is forecast to reach US$ 1,375.53 million by 2030, growing at a compound annual growth rate (CAGR) of 5.5% during the forecast period from 2022-2030.

A fetus' blood contains a liquid rich in nutrients called fetal bovine serum. Cell culture media commonly consist of fetal bovine serum (FBS), which derives from the fetuses of cows. It contains several nutritional and macromolecular factors necessary for cell growth. It also contains amino acids, sugars, lipids, hormones, and low levels of gamma globulin. Its uses are in various applications, including supplying essential nutrients and promoting cellular survival and growth in eukaryotic cell culture. Research, manufacturing, biotech drugs, and controlling vaccines for both humans and animals use this technology.

Factors Influencing Market Growth

A rise in R&D activities towards developing novel biopharmaceuticals and the growing pharmaceutical industry are forecast to drive the global fetal bovine serum market growth.
Developed and developing countries invest and fund more in research interventions, which encourages the global fetal bovine serum market growth.
A lack of skilled personnel and ethical concerns about misuse of biotechnology research practices may have a negative impact on the global fetal bovine serum market growth.
The untapped potential of emerging markets will likely turn out to be lucrative for the key players operating in the overall fetal bovine serum market in the near future.
Impact Analysis of COVID-19

A sudden increase in COVID-19 has significantly affected the growth of the global fetal bovine serum industry. The pandemic has increased the demand for fetal bovine serum, especially in biotechnological and biopharmaceutical facilities working on developing an effective vaccine against COVID-19. Growing demand for fetal bovine serum has driven the market's growth during the pandemic.

Regional Insights

In terms of geographic share, North America dominated the fetal bovine serum market in 2020 and is forecast to maintain its dominance during the forecast period. There has been a significant increase in R&D activities to develop antibody-based therapy for various diseases, and there is a well-established healthcare infrastructure in the region. In addition, market players in this region are increasing their investment in research and development activities related to drugs that require fetal bovine serum. These factors contribute to the growth of the fetal bovine serum market in the region.

Leading Competitors

The leading prominent companies profiled in the global fetal bovine serum market are:

Danaher (Cytiva)
Merck KGaA (Sigma Aldrich)
HiMedia Laboratories Pvt. Limited
Bio-Techne Corporation
Sera Scandia (Biowest)
Sartorius (Biological Industries)
Atlas Biologicals
Rocky Mountain Biologicals
PAN-Biotech
Thermo Fisher Scientific Incorporated
Other Prominent Players
Scope of the Report

The global fetal bovine serum market segmentation focuses on Application, End-User, and Region.

Segmentation based on Application

Biopharmaceuticals
Human and Animal Vaccine
Others (IVF and IVD)
Segmentation based on End-User

Biotechnology & Pharmaceutical Industries
Academic Institutes
Others (Research labs, Diagnostic labs, CRO, CMO, and IVF centers)
Segmentation based on Region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America